Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases

Abstract

Background: Solid cancers with bone marrow metastases are rare but lethal. This study aimed to identify clinical factors predictive of survival in adult patients with solid cancers and bone marrow metastases. Methods: A total of 83 patients were enrolled consecutively between January 1, 2000 and December 31, 2012. Bone marrow metastases were confirmed by biopsies. Patient clinical features and laboratory data were analyzed for associations. Results: The median age of the patients was 54 years (range, 23-88 years), and 58% were male. The 3 most common primary tumor locations were the stomach (32 patients, 39%), prostate (16 patients, 19%), and lungs (12 patients, 15%). The median overall survival was 49 days (range, 3-1423 days). Patients with Eastern Cooperative Oncology Group performance status 1, cancers of prostate origin, platelet counts over 50,000/ml, and undergoing antitumor therapies had a significantly better prognosis in the multivariate analysis. The median survival times were 173 and 33 days for patients with 2-3 more favorable parameters (n=24) and those with 0-1 (n=69), respectively (hazard ratio 0.30; 95% CI 0.17-0.52, p<0.001). Conclusions: Solid cancers with bone marrow metastases are dismal and incurable diseases. Understanding prognostic factors to these diseases helps medical personnel to provide appropriate treatments and better inform patients about outcomes. Antitumor therapies may improve outcomes in selected patient cohorts.

Base of tongue squamous cell carcinoma with infiltrative bone marrow carcinomatosis after definitive chemoradiation: A case report

“…Other solid tumors have been known to lead to bone marrow carcinomatosis, including breast, prostate, lung, and gastric cancers . In a study of prognostic factors in adult patients with solid tumor bone marrow metastases, antitumor therapy was associated with improved prognosis .…”

Nasopharyngeal Carcinoma with Bone Marrow Metastasis: Positive Response to Weekly Paclitaxel Chemotherapy

“…Chemotherapy consisting of 5-fluorouracil (5-FU) at a dose of 800 mg/m 2 /day for 5 days (days [1][2][3][4][5] and cisplatin at a dose of 50 mg/m 2 /day for 2 days (days 6-7) was initially administered, followed by radiotherapy (40 Gy in 20 fractions). The same chemotherapy regimen was used in the remaining treatments.…”

“…Bone marrow metastasis is a late-stage consequence of several types of solid tumors, including those of the lung, breast, prostate, and gastrointestinal tract (1)(2)(3). In general, bone marrow metastasis results in rapidly progressive disease with a poor prognosis (1).…”

“…In general, bone marrow metastasis results in rapidly progressive disease with a poor prognosis (1). A recent study in 83 consecutive patients with solid tumors and bone marrow metastasis reported a median overall survival of 49 days (3). In a cohort of 255 consecutive patients with nasopharyngeal carcinoma, bone marrow metastasis was found in 28 (11%) cases (4).…”

Coagulación intravascular diseminada asociada a cáncer gástrico metastásico: reporte de caso y revisión sistemática de la literatura

“…La infiltración a la médula ósea (IMO) es infrecuente en cánceres no hematológicos. Cáncer de próstata, mama, pulmón y estómago son los padecimientos oncológicos relacionados con mayor frecuencia a IMO 7 . Se ha informado prevalencia de IMO por CG del 0.024% 8 , en esos casos el pronóstico de supervivencia se limita a unos pocos días 9,10 .…”